Takeda Pharmaceutical Company Limited reported JPY 4.58T of revenue over the trailing twelve months, +43% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: JPY 4.58T (to FY2025). Net Income: JPY 107.9B, trailing twelve months to FY2025. Free Cash Flow: JPY 856.4B, trailing twelve months to FY2025. Op Margin: 7.5%, trailing twelve months to FY2025.

TAKTakeda Pharmaceutical Company Limited

HealthcareUSD

$18.25

$13.2352 weeks$18.80

TAK as reported

Takeda Pharmaceutical Company Limited reported JPY 4.58T of revenue over the trailing twelve months, +43% on the year before. 10 reported series are charted on this page, each one as filed.

JPY 4.58T

Revenue, trailing twelve months · to FY2025 · +43% against the twelve months before

Net Income: JPY 107.9B
Net Income · −71% year on year · trailing twelve months to FY2025
Free Cash Flow: JPY 856.4B
Free Cash Flow · −4.8% year on year · trailing twelve months to FY2025
Op Margin: 7.5%
Op Margin · trailing twelve months to FY2025

Every series Ryufin has for TAK, trailing twelve months
Series	Latest	Year on year	As of
Revenue	JPY 4.58T	+43%	FY2025
Net Income	JPY 107.9B	−71%	FY2025
EPS	JPY 67.23	−72%	FY2025
Gross Margin	66%	n/a	FY2025
Op Margin	7.5%	n/a	FY2025
Net Margin	2.4%	n/a	FY2025
ROE	1.6%	n/a	FY2025
ROA	0.76%	n/a	FY2025
ROIC	2.4%	n/a	FY2025
Free Cash Flow	JPY 856.4B	−4.8%	FY2025